Abstract
Rationale and objective
Depression is a significant complication of stroke. The effectiveness of antidepressant drugs in the management of post-stroke depression (PSD) has been widely investigated. However, the choice of antidepressant drug is critically influenced by its safety and tolerability and by its effect on concurrent pathologies. Here we investigate the efficacy and safety of a selective serotonin reuptake inhibitor (SSRI), citalopram, and a noradrenaline reuptake inhibitor (NARI), reboxetine, in post-stroke patients affected by anxious depression or retarded depression.
Methods
This was a randomized double-blind study. Seventy-four post-stroke depressed patients were diagnosed as affected by anxious or retarded depression by using a synoptic table. Randomisation was planned so that 50% of the patients in each subgroup were assigned for 16 weeks to treatment with citalopram and the remaining 50% were assigned to treatment with reboxetine. The Beck Depression Inventory (BDI), the Hamilton Depression Rating Scale (HDRS) and a synoptic table were used to score depressive symptoms.
Results
Both citalopram and reboxetine showed good safety and tolerability. Citalopram exhibited greater efficacy in anxious depressed patients, while reboxetine was more effective in retarded depressed patients.
Conclusions
Citalopram or other SSRIs and reboxetine may be of first choice treatment in PSD because of their good efficacy and lack of severe side effects. In addition, PSD patients should be classified according to their clinical profile (similarly to patients affected by primary depression) for the selection of SSRIs or reboxetine as drugs of choice in particular subgroups of patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Andersen G (1995) Treatment of uncontrolled crying after stroke. Drugs Aging 6:105–111
Andersen G, Vestergaard K, Riis JO (1993) Citalopram for post-stroke pathological crying. Lancet 342:837–839
Andersen G, Vestergaard K, Lauritzen L (1994) Effective treatment of poststroke depression with the selective serotonin reuptake inhibitor citalopram. Stroke 25:1099–1104
Andersen G, Vestergaard K, Ingemann-Nielsen M, Lauritzen L (1995a) Risk factors for post-stroke depression. Acta Psychiatr Scand 92:193–198
Andersen G, Vestergaard K, Lauritzen LU (1995b) Effective treatment of depression following apoplexy with citalopram. Ugeskr Laeger 157:2000–2003
Andreoli V, Carbognini G, Abati A, Vantini G (1999) Reboxetine in the treatment of depression in the elderly: a pilot study. J Geriatr Psychiatry Neurol 12:206–210
Barret AM (2000) Treatment of poststroke depression. JAMA 284:959
Breitner JC (2001) Vascular depression: new light on an established idea? J Neurol Neurosurg Psychiatry 70:3
Burrows GD, Maguire KP, Norman TR (1998) Antidepressant efficacy and tolerability of the selective norepinephrine reuptake inhibitor reboxetine: a review. J Clin Psychiatry 59:4–7
Carson AJ, MacHale S, Allen K, Lawrie SM, Dennis M, House A, Sharpe M (2000) Depression after stroke and lesion location: a systematic review. Lancet 356:122–126
Charatan FB, Fisk A (1978) Mental and emotional results of strokes. N Y State J Med 78:1403–1405
Dubini A, Bosc M, Polin V (1997) Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning. J Psychopharmacol 11:S17–23
Fruhwald S, Loffler H, Baumhackl U (1999) Depression after cerebrovascular injury. Review and differentiation from other psychiatric complications. Fortschr Neurol Psychiatr 67:155–162
Gainotti G, Azzoni A et al. (1997) Relation of lesion location to verbal and non verbal mood measures in stroke patients. Stroke 28:2145–2149
Gainotti G, Antonucci G, Marra C, Paolucci S (2001) Relation between depression after stroke, antidepressant therapy, and functional recovery. J Neurol Neurosurg Psychiatry 71:258–261
Goodnick PJ, Hernandez M (2000) Treatment of depression in comorbid medical illness. Exp Opin Pharmacother 7:1367–1384
Jolobe OM (1998) Depression and its relation to lesion location after stroke. J Neurol Neurosurg Psychiatry 65:410
Kasper S, Giamal N, Hilger E (2000) Reboxetine: the first selective noradrenaline re-uptake inhibitor. Exp Opin Pharmacother 1:771–782
Kimura M, Robinson RG, Kosier JT (2000) Treatment of cognitive impairment after post-stroke depression: a double-blind treatment trial. Stroke 31:1482–1486
Lyketsos CG, Treisman GJ, Lipsey JR, Morris PL, Robinson RG (1998) Does stroke cause depression? J Neuropsychiatr Clin Neurosci 10:103–107
Rampello L, Nicoletti G, Raffaele R (1991) Dopaminergic hypothesis for retarded depression: a symptom profile for predicting therapeutical responses. Acta Psychiatr Scand 84:552–554
Rampello L, Nicoletti G, Raffaele R, Drago F (1995) Comparative effects of amitriptyline and amineptine in patients affected by anxious depression. Neuropsychobiology 31:130–134
Rampello L, Nicoletti F, Nicoletti F (2000) Dopamine and depression. Therapeutic implications. CNS Drugs 13:35–45
Rigler SK (1999) Management of poststroke depression in older people. Clin Geriatr Med 15:765–783
Robinson RG (1997) Neuropsychiatric consequences of stroke. Annu Rev Med 48:217–229
Robinson RG, Morris PLP, Fedoroff P (1990) Depression and cerebrovascular disease. J Clin Psychiatry 51:26–31
Scates AC, Doraiswamy PM (2000) Reboxetine: a selective norepinephrine reuptake inhibitor for the treatment of depression. Ann Pharmacother 34:1302–1312
Sunnybrook Stroke Study (2000) Functional and neuroanatomic correlations in poststroke depression. Stroke 31:637
Wiart L, Petit H, Joseph PA et al. (2000) Fluoxetine in early post-stroke depression. A double-blind placebo-controlled study. Stroke 31:1829–1832
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rampello, L., Chiechio, S., Nicoletti, G. et al. Prediction of the response to citalopram and reboxetine in post-stroke depressed patients. Psychopharmacology 173, 73–78 (2004). https://doi.org/10.1007/s00213-003-1698-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-003-1698-1